NCI Drug Dictionary

The NCI Drug Dictionary contains technical definitions and synonyms for drugs/agents used to treat patients with cancer or conditions related to cancer. Each drug entry includes links to check for clinical trials listed in NCI's List of Cancer Clinical Trials.

C3-targeted complement inhibitor APL-2
A pegylated derivative of the cyclic tridecapeptide compstatin and inhibitor of complement component C3 (C3) activation, with potential use as a treatment for various diseases in which excessive complement activation plays a key role, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD). Upon administration, C3-targeted complement inhibitor APL-2 selectively binds to C3 and blocks the cleavage of C3 into C3a and C3b by C3 convertase. This prevents complement pathway activation, and inhibits complement-mediated inflammation and cell lysis. Pegylation increases compstatin's half-life, and increases its efficacy. Excessive complement activation plays a key role in various inflammatory and autoimmune diseases, and leads to tissue destruction. C3 is a crucial and central component of the complement system. Check for active clinical trials using this agent. (NCI Thesaurus)

Code name:APL2